BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33173219)

  • 21. [Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].
    Shang Z; Wang D; Xiao M; Wang J; Li TJ; Zhao YC; Li CR; Zhou JF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):607-12. PubMed ID: 23815907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
    Thol F; Damm F; Wagner K; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Heil G; Heuser M; Krauter J; Ganser A
    Blood; 2010 Jul; 116(4):614-6. PubMed ID: 20421455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
    Wang RX; Wu DP; Chen SN; He J; Xu Y; Wang XL; Yin J; Tian H; Tian XP; Sun AN
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):751-5. PubMed ID: 23755812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
    Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
    Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
    Wang F; Travins J; DeLaBarre B; Penard-Lacronique V; Schalm S; Hansen E; Straley K; Kernytsky A; Liu W; Gliser C; Yang H; Gross S; Artin E; Saada V; Mylonas E; Quivoron C; Popovici-Muller J; Saunders JO; Salituro FG; Yan S; Murray S; Wei W; Gao Y; Dang L; Dorsch M; Agresta S; Schenkein DP; Biller SA; Su SM; de Botton S; Yen KE
    Science; 2013 May; 340(6132):622-6. PubMed ID: 23558173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
    Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
    Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of IDH mutations in acute myeloid leukemia.
    Montalban-Bravo G; DiNardo CD
    Future Oncol; 2018 Apr; 14(10):979-993. PubMed ID: 29543066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Author Correction: Mir142 loss unlocks IDH2
    Marshall A; Kasturiarachchi J; Datta P; Guo Y; Deltcheva E; James C; Brown J; May G; Anandagoda N; Jackson I; Howard JK; Ghazaly E; Brooks S; Khwaja A; Araki M; Araki K; Linch D; Lord GM; Enver T; Nimmo R
    Sci Rep; 2021 Mar; 11(1):6974. PubMed ID: 33753768
    [No Abstract]   [Full Text] [Related]  

  • 29. IDH2 inhibition in AML: Finally progress?
    Stein EM
    Best Pract Res Clin Haematol; 2015; 28(2-3):112-5. PubMed ID: 26590767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
    Zou Y; Zeng Y; Zhang DF; Zou SH; Cheng YF; Yao YG
    Biochem Biophys Res Commun; 2010 Nov; 402(2):378-83. PubMed ID: 20946881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes.
    Wang GG; Pasillas MP; Kamps MP
    Mol Cell Biol; 2006 May; 26(10):3902-16. PubMed ID: 16648484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
    Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
    Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells.
    Schneider E; Pochert N; Ruess C; MacPhee L; Escano L; Miller C; Krowiorz K; Delsing Malmberg E; Heravi-Moussavi A; Lorzadeh A; Ashouri A; Grasedieck S; Sperb N; Kumar Kopparapu P; Iben S; Staffas A; Xiang P; Rösler R; Kanduri M; Larsson E; Fogelstrand L; Döhner H; Döhner K; Wiese S; Hirst M; Keith Humphries R; Palmqvist L; Kuchenbauer F; Rouhi A
    Leukemia; 2020 May; 34(5):1253-1265. PubMed ID: 31768018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CTCF boundary remodels chromatin domain and drives aberrant
    Luo H; Wang F; Zha J; Li H; Yan B; Du Q; Yang F; Sobh A; Vulpe C; Drusbosky L; Cogle C; Chepelev I; Xu B; Nimer SD; Licht J; Qiu Y; Chen B; Xu M; Huang S
    Blood; 2018 Aug; 132(8):837-848. PubMed ID: 29760161
    [No Abstract]   [Full Text] [Related]  

  • 35. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
    Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
    Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
    Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
    Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
    Patel KP; Ravandi F; Ma D; Paladugu A; Barkoh BA; Medeiros LJ; Luthra R
    Am J Clin Pathol; 2011 Jan; 135(1):35-45. PubMed ID: 21173122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.
    Damm F; Thol F; Hollink I; Zimmermann M; Reinhardt K; van den Heuvel-Eibrink MM; Zwaan CM; de Haas V; Creutzig U; Klusmann JH; Krauter J; Heuser M; Ganser A; Reinhardt D; Thiede C
    Leukemia; 2011 Nov; 25(11):1704-10. PubMed ID: 21647152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia.
    Bi L; Zhou B; Li H; He L; Wang C; Wang Z; Zhu L; Chen M; Gao S
    BMC Cancer; 2018 Feb; 18(1):182. PubMed ID: 29439669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.
    Yoshimi A; Lin KT; Wiseman DH; Rahman MA; Pastore A; Wang B; Lee SC; Micol JB; Zhang XJ; de Botton S; Penard-Lacronique V; Stein EM; Cho H; Miles RE; Inoue D; Albrecht TR; Somervaille TCP; Batta K; Amaral F; Simeoni F; Wilks DP; Cargo C; Intlekofer AM; Levine RL; Dvinge H; Bradley RK; Wagner EJ; Krainer AR; Abdel-Wahab O
    Nature; 2019 Oct; 574(7777):273-277. PubMed ID: 31578525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.